131 results
Page 3 of 7
8-K
EX-99.3
2gb70qaa0canj
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.2
opnt2h
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
S-3ASR
EX-1.2
o1n3jgn
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
ifwvh3qqfcv7 bs
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
8-K
EX-99.1
9g7dgpov7pmtga iw8z
13 Jan 20
Regulation FD Disclosure
4:32pm
8-K
EX-99.2
ktik508n rk9
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
669lak
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.3
icre9fip
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
f6ogyr0s
22 Nov 19
Other Events
5:01pm
424B5
8alhgtjrr ie4jod7
8 Nov 19
Prospectus supplement for primary offering
5:03pm
8-K
EX-1.1
6hq5juxwly86 81zje3i
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
424B5
tr68xi4kbw
6 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
e11d udmdc
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
w2r2n
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
qkovy72
4 Sep 19
Other Events
5:05pm